# Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

> **NCT00264849** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 406 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab
- **OTHER:** Optimized asthma therapy

## Key facts

- **NCT ID:** NCT00264849
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2018-06-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00264849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00264849, "Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00264849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*